Trexquant Investment LP Purchases 364,990 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST)

Trexquant Investment LP grew its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 111.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 692,037 shares of the company's stock after acquiring an additional 364,990 shares during the period. Trexquant Investment LP owned 0.18% of LifeStance Health Group worth $5,100,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LFST. Blue Trust Inc. lifted its position in shares of LifeStance Health Group by 124.4% during the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after buying an additional 2,122 shares during the period. Townsquare Capital LLC acquired a new position in LifeStance Health Group in the third quarter worth $73,000. R Squared Ltd acquired a new stake in shares of LifeStance Health Group in the fourth quarter valued at $80,000. Cibc World Markets Corp bought a new position in shares of LifeStance Health Group in the fourth quarter valued at about $96,000. Finally, Handelsbanken Fonder AB acquired a new position in LifeStance Health Group during the 4th quarter worth about $128,000. Institutional investors and hedge funds own 85.50% of the company's stock.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.90, for a total value of $130,030.50. Following the sale, the insider now owns 339,810 shares in the company, valued at approximately $2,344,689. The trade was a 5.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.60% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have recently commented on LFST shares. The Goldman Sachs Group raised shares of LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $10.00 price target on the stock in a research note on Monday, December 16th. William Blair reissued an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. Canaccord Genuity Group began coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They set a "buy" rating and a $8.00 price target on the stock. Finally, KeyCorp began coverage on LifeStance Health Group in a research report on Tuesday. They issued an "overweight" rating and a $9.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.58.

LifeStance Health Group Stock Down 3.7 %

NASDAQ LFST traded down $0.26 during trading hours on Thursday, reaching $6.66. 947,186 shares of the company's stock were exchanged, compared to its average volume of 1,594,838. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. LifeStance Health Group, Inc. has a one year low of $4.64 and a one year high of $8.61. The company's 50-day moving average is $7.33 and its two-hundred day moving average is $7.33. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -25.61 and a beta of 1.30.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.